Hypochondroplasia

👪

Inheritance

1

Autosomal dominant

Hypochondroplasia follows autosomal dominant inheritance. Many cases are de novo mutations. Compound heterozygosity for achondroplasia and hypochondroplasia alleles results in an intermediate phenotype more severe than hypochondroplasia alone.

Show evidence (1 reference)

PMID:41184854 SUPPORT Human Clinical

"Overall, 85.5% of ACH cases and 57.2% of HCH cases were related to de novo genetic variants"

Nationwide French registry data shows that 57.2% of HCH cases arise from de novo variants, consistent with autosomal dominant inheritance with frequent new mutations.

⚙

Pathophysiology

5

FGFR3 constitutive activation

The FGFR3 N540K mutation causes constitutive activation of the receptor tyrosine kinase, resulting in ligand-independent FGFR3 signaling in growth plate chondrocytes, osteoblasts, and other skeletal cells.

Growth plate chondrocyte link

FGFR signaling pathway link ↑ INCREASED

Downstream

MAPK/ERK cascade hyperactivation

Defective bone mineralization

Cranial base synchondrosis dysfunction

Show evidence (2 references)

PMID:29063142 SUPPORT Other

"The FGFR3 gene encodes fibroblast growth factor receptor 3 protein, a negative regulator of chondrogenesis. Gain-of-function mutations result in constitutively activated FGFR3, leading to aberrant signal transduction, and accounting for inhibition of chondrocyte proliferation and differentiation."

Comprehensive review of FGFR3 molecular pathology establishing that gain-of-function mutations cause constitutive activation leading to impaired chondrocyte proliferation and differentiation.

PMID:37345656 SUPPORT Model Organism

"Hypochondroplasia (HCH) is a mild dwarfism caused by missense mutations in fibroblast growth factor receptor 3 (FGFR3), with the majority of cases resulting from a heterozygous p.Asn540Lys gain-of-function mutation."

The first HCH mouse model confirms that the Asn540Lys gain-of-function mutation is sufficient to cause progressive dwarfism via FGFR3 activation.

MAPK/ERK cascade hyperactivation

Constitutively activated FGFR3 drives hyperactivation of the Ras-MAPK/ERK signaling cascade in growth plate chondrocytes, suppressing chondrocyte proliferation and differentiation.

Growth plate chondrocyte link

MAPK cascade link ↑ INCREASED

Downstream

Impaired endochondral ossification

Show evidence (1 reference)

PMID:29063142 SUPPORT Other

"Gain-of-function mutations result in constitutively activated FGFR3, leading to aberrant signal transduction, and accounting for inhibition of chondrocyte proliferation and differentiation."

The FGFR3 therapeutic review establishes that aberrant MAPK/ERK signal transduction downstream of activated FGFR3 inhibits chondrocyte proliferation and differentiation.

Impaired endochondral ossification

Suppressed chondrocyte proliferation and altered hypertrophic differentiation downstream of MAPK/ERK hyperactivation impair endochondral ossification, reducing longitudinal bone growth and causing short stature.

Growth plate chondrocyte link

Endochondral ossification link ↓ DECREASED

Show evidence (1 reference)

PMID:37345656 SUPPORT Model Organism

"Fgfr3Asn534Lys/+ mice exhibited progressive dwarfism and impairment of the synchondroses of the cranial base, resulting in defective formation of the foramen magnum."

The HCH mouse model demonstrates that FGFR3 gain-of-function causes progressive dwarfism through impaired endochondral ossification.

Defective bone mineralization

FGFR3 activation alters osteoblast and osteocyte function, leading to decreased trabecular bone mineral density in long bones and vertebrae, with a paradoxical age-related increase in cortical BMD accompanied by reduced toughness. These changes produce bone with osteoporosis-like characteristics.

Osteoblast link Osteocyte link

Bone mineralization link ↓ DECREASED

Show evidence (1 reference)

PMID:37345656 SUPPORT Model Organism

"Trabecular bone mineral density (BMD) of long bones and vertebral bodies was decreased, but cortical BMD increased with age in both tibiae and femurs. These results demonstrate that bones in Fgfr3Asn534Lys/+ mice, due to FGFR3 activation, exhibit some characteristics of osteoporosis."

The HCH mouse model reveals a complex bone mineralization phenotype with decreased trabecular BMD and paradoxically increased cortical BMD with reduced mechanical toughness, suggesting osteoporosis risk in aging HCH patients.

Cranial base synchondrosis dysfunction

FGFR3 activation impairs the synchondroses of the cranial base, leading to premature closure and defective formation of the foramen magnum. This contributes to relative macrocephaly and potential foramen magnum stenosis.

Growth plate chondrocyte link

Endochondral ossification link ↓ DECREASED

Show evidence (1 reference)

PMID:37345656 SUPPORT Model Organism

"Fgfr3Asn534Lys/+ mice exhibited progressive dwarfism and impairment of the synchondroses of the cranial base, resulting in defective formation of the foramen magnum."

Mouse model demonstrates that FGFR3 gain-of-function directly disrupts cranial base synchondrosis development and foramen magnum formation, explaining the craniofacial features of HCH.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

16

Head and Neck 1

Relative macrocephaly HP_0040282 Relative macrocephaly (HP:0004482)

Show evidence (3 references)

PMID:41040055 SUPPORT Human Clinical

"The mean (SD) HCH-I was -3.0 (1.2) in the HCH cohort, compared to -0.2 (0.9) in the CIGS cohort. An HCH-I below -2 correctly identified 78% of children with HCH, while only 2.4% of CIGS children fell below the cut-off."

This large 2026 cohort study shows marked head-height disproportion in HCH, directly supporting relative macrocephaly as a characteristic phenotype.

PMID:36442838 SUPPORT Human Clinical

"Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively."

Macrocephaly was observed in 9/20 patients (45%), which falls in the FREQUENT band.

PMID:41762373 SUPPORT Other

"features suggestive of HCH include a sustained fall in length/height centiles over the first 2 years of life, relative macrocephaly, neonatal seizures, and specific radiographic and neuroimaging findings."

Expert consensus identifies relative macrocephaly as a key feature suggestive of HCH.

Limbs 3

Genu varum HP_0040282 Genu varum (HP:0002970)

Show evidence (1 reference)

PMID:36442838 SUPPORT Human Clinical

"Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively."

Genu varum was observed in 11/20 patients (55%), which falls in the FREQUENT band.

Metaphyseal widening Metaphyseal widening (HP:0003016)

Show evidence (2 references)

PMID:20301650 SUPPORT Other

"Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."

GeneReviews describes mild metaphyseal flare as a characteristic long-bone radiographic feature.

PMID:11475794 SUPPORT Other

"Hypochondroplasia is a genetic skeletal dysplasia characterized by disproportionate short stature, stocky appearance and several clinical and radiological features very similar, but much milder, than those of classical achondroplasia, including shortened and stubby long bones, decreased..."

An independent radiology review also highlights metaphyseal flaring in hypochondroplasia.

Short femur Short femur (HP:0003097)

Show evidence (2 references)

PMID:26867606 SUPPORT Human Clinical

"We evaluated parameters reflecting the presence of (1) short ilia, (2) squared ilia, (3) short greater sciatic notch, (4) horizontal acetabula, (5) short femora, (6) broad femora, (7) metaphyseal flaring, (8) lumbosacral interpedicular distance narrowing and (9) ovoid radiolucency of the..."

This abstract explicitly defines parameter 5 as short femora and reports it among the radiographic features that significantly distinguished HCH neonates from controls.

PMID:14755409 SUPPORT Human Clinical

"Mild shortening of the limbs became manifest after 26 weeks of gestation."

This molecularly confirmed prenatal case supports femoral/limb shortening as an early developmental manifestation.

Musculoskeletal 2

Mild joint laxity Joint hypermobility (HP:0001382)

Show evidence (1 reference)

PMID:20301650 SUPPORT Other

"Hypochondroplasia is a skeletal dysplasia characterized by short stature; stocky build; disproportionately short arms and legs; broad, short hands and feet; mild joint laxity; and relative macrocephaly."

GeneReviews lists mild joint laxity among the characteristic clinical features of hypochondroplasia.

Spinal canal stenosis Spinal canal stenosis (HP:0003416)

Show evidence (1 reference)

PMID:20301650 SUPPORT Other

"Medical complications common to achondroplasia (e.g., foramen magnum stenosis, spinal stenosis, tibial bowing, obstructive apnea) occur less frequently in hypochondroplasia, but intellectual disability and epilepsy may be more prevalent."

GeneReviews explicitly lists spinal stenosis among recognized but less frequent hypochondroplasia complications.

Nervous System 5

Neurodevelopmental delay HP_0040283 Neurodevelopmental delay (HP:0012758)

Show evidence (3 references)

PMID:36442838 SUPPORT Human Clinical

"Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively."

Developmental delay was observed in 5/20 patients (25%), which falls in the OCCASIONAL band.

PMID:23165795 SUPPORT Human Clinical

"Eight patients had neurocognitive difficulties, ranging from specific learning disorder (2/13) to mild intellectual disability (5/13) or global developmental delay (1/13)."

A neurologically evaluated Finnish FGFR3 N540K cohort showed a broader spectrum of neurocognitive difficulties, reinforcing neurodevelopmental involvement.

PMID:41762373 SUPPORT Other

"Neurocognitive involvement including neurodevelopmental challenges may become apparent."

Expert consensus recognizes neurodevelopmental challenges as part of the HCH phenotype.

Seizures Seizure (HP:0001250)

Show evidence (2 references)

PMID:23165795 SUPPORT Human Clinical

"Six of 13 patients had a history of seizures or epilepsy."

Seizures/epilepsy were documented in a neurologically selected Finnish FGFR3 N540K cohort, supporting a real but frequency-uncertain association.

PMID:20301650 SUPPORT Other

"Infants may present with temporal lobe seizures."

GeneReviews notes that seizures can be an early presenting manifestation.

Temporal lobe dysplasia Temporal lobe dysplasia (HP:0034222)

Show evidence (1 reference)

PMID:23165795 SUPPORT Human Clinical

"Eight patients had undergone MRI. They all had structural abnormalities consistent with temporal lobe dysgenesis."

All eight imaged patients in this neurologically selected FGFR3 N540K cohort had temporal lobe dysgenesis on MRI, establishing the association but not an unbiased population frequency.

Ventriculomegaly Ventriculomegaly (HP:0002119)

Show evidence (1 reference)

PMID:23165795 SUPPORT Human Clinical

"Six patients had peritrigonal white matter reduction, and 4 had abnormally shaped lateral ventricles."

Abnormally shaped lateral ventricles were observed on MRI in four neurologically evaluated patients with FGFR3 N540K-related HCH.

Hydrocephalus Hydrocephalus (HP:0000238)

Show evidence (1 reference)

PMID:36442838 SUPPORT Human Clinical

"Of the 12 patients who underwent neuroimaging, five (41.7%) showed abnormal findings (one required operation for obstructive hydrocephalus)."

One child in this 20-patient Korean cohort required surgery for obstructive hydrocephalus, showing that hydrocephalus can occur as a clinically important complication.

Growth 2

Short stature Short stature (HP:0004322)

Show evidence (3 references)

PMID:20301650 SUPPORT Other

"Hypochondroplasia is a skeletal dysplasia characterized by short stature; stocky build; disproportionately short arms and legs; broad, short hands and feet; mild joint laxity; and relative macrocephaly."

GeneReviews identifies short stature as part of the core clinical phenotype of hypochondroplasia.

PMID:36442838 SUPPORT Human Clinical

"The patients presented with a short stature and/or short limbs."

In this Korean FGFR3 N540K cohort, short stature and/or short limbs were the presenting growth abnormality.

PMID:41762373 SUPPORT Other

"Hypochondroplasia (HCH) is a disproportionate short-statured skeletal dysplasia condition caused by gain-of-function pathogenic variants in the fibroblast growth receptor 3 gene (FGFR3)."

Expert consensus likewise frames HCH as a disproportionate short-stature disorder.

Rhizomelic limb shortening Rhizomelia (HP:0008905)

Show evidence (2 references)

PMID:14755409 SUPPORT Human Clinical

"Hypochondroplasia is an autosomal dominant skeletal dysplasia expressing postnatal onset of short stature with mild rhizomelic shortening of the limbs."

A molecularly confirmed neonatal case report documents mild rhizomelic limb shortening as an early manifestation.

PMID:41762373 SUPPORT Other

"Between ages 2-3 years, a characteristic growth pattern including limb shortening and body disproportion may become evident."

Expert consensus states that limb shortening and body disproportion typically become clinically apparent between ages 2 and 3 years.

Other 3

Narrow vertebral interpedicular distance Narrow vertebral interpedicular distance (HP:0008450)

Show evidence (2 references)

PMID:20301650 SUPPORT Other

"Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."

GeneReviews identifies lack of widening or narrowing of the lumbar interpedicular distances as a characteristic radiographic feature.

PMID:11475794 SUPPORT Other

"Hypochondroplasia is a genetic skeletal dysplasia characterized by disproportionate short stature, stocky appearance and several clinical and radiological features very similar, but much milder, than those of classical achondroplasia, including shortened and stubby long bones, decreased..."

This radiology-focused review independently confirms decreased lumbosacral interpediculate distance as a salient hypochondroplasia sign.

Posterior scalloping of vertebral bodies Posterior scalloping of vertebral bodies (HP:0005121)

Show evidence (2 references)

PMID:20301650 SUPPORT Other

"Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."

GeneReviews lists posterior scalloping of the vertebral bodies among the core radiographic features.

PMID:11475794 SUPPORT Other

"Hypochondroplasia is a genetic skeletal dysplasia characterized by disproportionate short stature, stocky appearance and several clinical and radiological features very similar, but much milder, than those of classical achondroplasia, including shortened and stubby long bones, decreased..."

A radiology review likewise identifies posterior scalloping of the lumbar vertebrae as part of the classic pattern.

Short iliac bones Short iliac bones (HP:0100866)

Show evidence (2 references)

PMID:20301650 SUPPORT Other

"Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."

GeneReviews identifies squared, shortened ilia as part of the classic HCH pelvic phenotype.

PMID:26867606 SUPPORT Human Clinical

"We evaluated parameters reflecting the presence of (1) short ilia, (2) squared ilia, (3) short greater sciatic notch, (4) horizontal acetabula, (5) short femora, (6) broad femora, (7) metaphyseal flaring, (8) lumbosacral interpedicular distance narrowing and (9) ovoid radiolucency of the..."

This abstract explicitly defines parameter 1 as short ilia and reports it among the radiographic features that significantly distinguished HCH neonates from controls.

🧬

Genetic Associations

2

FGFR3 N540K mutation (Causative)

Show evidence (3 references)

PMID:7670477 SUPPORT Human Clinical

"We now report a single FGFR3 mutation found in 8 out of 14 unrelated patients with hypochondroplasia. This mutation causes a C to A transversion at nucleotide 1620, resulting in an Asn540Lys substitution in the proximal tyrosine kinase domain."

Landmark Nature Genetics paper identifying the recurrent FGFR3 N540K mutation as the cause of hypochondroplasia in the majority of genetically confirmed cases.

PMID:36442838 SUPPORT Human Clinical

"The N540K variant accounts for 60-70% of reported cases and is associated with severe manifestations."

Korean clinical series confirms the high frequency of the N540K variant among genetically confirmed HCH cases.

PMID:41184854 SUPPORT Human Clinical

"Overall, 85.5% of ACH cases and 57.2% of HCH cases were related to de novo genetic variants"

French nationwide data confirms that the majority of HCH cases arise from de novo FGFR3 variants.

FGFR3 (Pathogenic Variants)

Show evidence (1 reference)

CGGV:assertion_518a0eb2-f7ea-40e8-acad-afc34f5b188e-2023-09-28T040000.000Z SUPPORT Other

ClinGen classifies the FGFR3-hypochondroplasia gene-disease relationship as definitive with autosomal dominant inheritance.

💊

Treatments

3

Vosoritide (CNP analog)

Action: CNP analog therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: vosoritide ↗

Vosoritide is a C-type natriuretic peptide (CNP) analog that counteracts FGFR3 overactivation by stimulating the NPR2/cGMP pathway, which antagonizes MAPK/ERK signaling in growth plate chondrocytes. A phase 2 trial demonstrated a 1.81 cm/year increase in annualized growth velocity with acceptable safety.

Show evidence (1 reference)

PMID:38813446 SUPPORT Human Clinical

"Vosoritide was well tolerated with no treatment-related serious adverse events. Injection site reactions occurred in 83.3% of participants. No participants discontinued therapy due to an adverse event. Annualized growth velocity increased by 2.26 standard deviations (SD) and height SDS increased..."

Phase 2 trial in 24 children with HCH demonstrated that vosoritide significantly increased growth velocity with a favorable safety profile.

Growth hormone therapy

Action: Growth hormone therapy Ontology label: human growth hormone replacement therapy MAXO:0000780

Recombinant human growth hormone has been used with variable response. In one Korean cohort, 16 patients treated for a mean of 5.4 years showed a significant increase in height standard deviation scores.

Show evidence (1 reference)

PMID:36442838 SUPPORT Human Clinical

"Among 16 growth-hormone-treated patients (two were growth-hormone deficient), the increase in height standard deviation scores was significant after a mean 5.4±0.7 years of treatment (+0.6 and+1.8 using growth references for healthy controls and achondroplasia children, respectively)."

Korean cohort data shows statistically significant height gains with GH therapy in HCH, though the magnitude of improvement is modest.

Orthopedic management

Action: Orthopedic surgery Ontology label: surgical procedure MAXO:0000004

Surgical correction of leg bowing or other skeletal deformities may be considered if functionally significant. Surgical limb lengthening has been performed in some patients.

Show evidence (1 reference)

PMID:36442838 SUPPORT Human Clinical

"Four patients underwent surgical limb lengthening at a mean age of 8.8±3.3 years."

Surgical limb lengthening was performed in 4 of 20 Korean HCH patients, typically in mid-childhood.

🔬

Clinical Trials

1

NCT04219007 PHASE_II COMPLETED

Single-arm, open-label phase 2 trial evaluating the safety and efficacy of vosoritide (15 μg/kg/day subcutaneous injection) in children with hypochondroplasia, following a 6-month observation period and 12 months of treatment.

Target Phenotypes: Short stature ↗

Show evidence (1 reference)

PMID:38813446 SUPPORT Human Clinical

"We conducted a single-arm, phase 2, open-label trial at a single centre in the USA and enrolled 26 children with hypochondroplasia."

This trial established efficacy of vosoritide for growth velocity improvement in HCH children, similar to results in achondroplasia.

{ }

Source YAML

click to show

name: Hypochondroplasia
creation_date: '2026-02-02T00:16:36Z'
updated_date: '2026-04-19T00:33:11Z'
category: Mendelian
description: >
  Hypochondroplasia is a milder FGFR3-related skeletal dysplasia characterized by
  proportionate or mildly disproportionate short stature, with less pronounced features
  than achondroplasia. The most common mutation is FGFR3 N540K (c.1620C>A or c.1620C>G),
  found in approximately 50-70% of clinically diagnosed cases. Unlike achondroplasia,
  the phenotype is variable and may not be recognized until later childhood. Macrocephaly
  is less prominent, and spinal stenosis is less common. The diagnosis may be challenging
  in individuals with subtle features.
disease_term:
  preferred_term: hypochondroplasia
  term:
    id: MONDO:0007793
    label: hypochondroplasia
parents:
- FGFR3-related skeletal dysplasia
inheritance:
- name: Autosomal dominant
  description: >
    Hypochondroplasia follows autosomal dominant inheritance. Many cases are de novo
    mutations. Compound heterozygosity for achondroplasia and hypochondroplasia alleles
    results in an intermediate phenotype more severe than hypochondroplasia alone.
  evidence:
  - reference: PMID:41184854
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, 85.5% of ACH cases and 57.2% of HCH cases were related to de novo genetic variants"
    explanation: >
      Nationwide French registry data shows that 57.2% of HCH cases arise from de novo
      variants, consistent with autosomal dominant inheritance with frequent new mutations.
prevalence:
- population: French pediatric live births (2008-2023)
  percentage: 1.31 per 100,000
  notes: >-
    The first nationwide French registry analysis estimated a mean live-birth
    prevalence of 1.31 per 100,000 for hypochondroplasia, while noting that milder
    postnatally diagnosed forms may still be under-recognized.
  evidence:
  - reference: PMID:41184854
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To estimate live birth prevalence, we focused on pediatric patients (0-15 years) born between 2008 and 2023. The mean (range) live birth prevalence was 3.27 per 100,000 for ACH (1.90-4.03) and 1.31 per 100,000 for HCH (0.54-2.08)."
    explanation: This nationwide French rare-disease registry study provides the clearest disease-specific birth prevalence estimate for hypochondroplasia.
pathophysiology:
- name: FGFR3 constitutive activation
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Constitutive FGFR Activation"
  description: >
    The FGFR3 N540K mutation causes constitutive activation of the receptor tyrosine
    kinase, resulting in ligand-independent FGFR3 signaling in growth plate
    chondrocytes, osteoblasts, and other skeletal cells.
  gene:
    preferred_term: FGFR3
    description: Fibroblast growth factor receptor 3 with activating mutation causing gain-of-function.
    modifier: INCREASED
    term:
      id: hgnc:3690
      label: FGFR3
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: FGFR signaling pathway
    term:
      id: GO:0008543
      label: fibroblast growth factor receptor signaling pathway
    modifier: INCREASED
  downstream:
  - target: MAPK/ERK cascade hyperactivation
  - target: Defective bone mineralization
  - target: Cranial base synchondrosis dysfunction
  evidence:
  - reference: PMID:29063142
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The FGFR3 gene encodes fibroblast growth factor receptor 3 protein, a negative regulator of chondrogenesis. Gain-of-function mutations result in constitutively activated FGFR3, leading to aberrant signal transduction, and accounting for inhibition of chondrocyte proliferation and differentiation."
    explanation: >
      Comprehensive review of FGFR3 molecular pathology establishing that gain-of-function
      mutations cause constitutive activation leading to impaired chondrocyte proliferation
      and differentiation.
  - reference: PMID:37345656
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Hypochondroplasia (HCH) is a mild dwarfism caused by missense mutations in fibroblast growth factor receptor 3 (FGFR3), with the majority of cases resulting from a heterozygous p.Asn540Lys gain-of-function mutation."
    explanation: >
      The first HCH mouse model confirms that the Asn540Lys gain-of-function mutation
      is sufficient to cause progressive dwarfism via FGFR3 activation.
- name: MAPK/ERK cascade hyperactivation
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Sustained MAPK/STAT Signaling"
  description: >
    Constitutively activated FGFR3 drives hyperactivation of the Ras-MAPK/ERK
    signaling cascade in growth plate chondrocytes, suppressing chondrocyte
    proliferation and differentiation.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: MAPK cascade
    term:
      id: GO:0000165
      label: MAPK cascade
    modifier: INCREASED
  downstream:
  - target: Impaired endochondral ossification
  evidence:
  - reference: PMID:29063142
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Gain-of-function mutations result in constitutively activated FGFR3, leading to aberrant signal transduction, and accounting for inhibition of chondrocyte proliferation and differentiation."
    explanation: >
      The FGFR3 therapeutic review establishes that aberrant MAPK/ERK signal transduction
      downstream of activated FGFR3 inhibits chondrocyte proliferation and differentiation.
- name: Impaired endochondral ossification
  conforms_to: "fgfr_gain_of_function_skeletal_dysplasia#Impaired Endochondral Ossification and Chondrodysplasia"
  description: >
    Suppressed chondrocyte proliferation and altered hypertrophic differentiation
    downstream of MAPK/ERK hyperactivation impair endochondral ossification,
    reducing longitudinal bone growth and causing short stature.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: Endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  evidence:
  - reference: PMID:37345656
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Fgfr3Asn534Lys/+ mice exhibited progressive dwarfism and impairment of the synchondroses of the cranial base, resulting in defective formation of the foramen magnum."
    explanation: >
      The HCH mouse model demonstrates that FGFR3 gain-of-function causes progressive
      dwarfism through impaired endochondral ossification.
- name: Defective bone mineralization
  description: >
    FGFR3 activation alters osteoblast and osteocyte function, leading to decreased
    trabecular bone mineral density in long bones and vertebrae, with a paradoxical
    age-related increase in cortical BMD accompanied by reduced toughness. These changes
    produce bone with osteoporosis-like characteristics.
  cell_types:
  - preferred_term: Osteoblast
    term:
      id: CL:0000062
      label: osteoblast
  - preferred_term: Osteocyte
    term:
      id: CL:0000137
      label: osteocyte
  biological_processes:
  - preferred_term: Bone mineralization
    term:
      id: GO:0030282
      label: bone mineralization
    modifier: DECREASED
  evidence:
  - reference: PMID:37345656
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Trabecular bone mineral density (BMD) of long bones and vertebral bodies was decreased, but cortical BMD increased with age in both tibiae and femurs. These results demonstrate that bones in Fgfr3Asn534Lys/+ mice, due to FGFR3 activation, exhibit some characteristics of osteoporosis."
    explanation: >
      The HCH mouse model reveals a complex bone mineralization phenotype with decreased
      trabecular BMD and paradoxically increased cortical BMD with reduced mechanical
      toughness, suggesting osteoporosis risk in aging HCH patients.
- name: Cranial base synchondrosis dysfunction
  description: >
    FGFR3 activation impairs the synchondroses of the cranial base, leading to premature
    closure and defective formation of the foramen magnum. This contributes to relative
    macrocephaly and potential foramen magnum stenosis.
  cell_types:
  - preferred_term: Growth plate chondrocyte
    term:
      id: CL:1000217
      label: growth plate cartilage chondrocyte
  biological_processes:
  - preferred_term: Endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
    modifier: DECREASED
  evidence:
  - reference: PMID:37345656
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Fgfr3Asn534Lys/+ mice exhibited progressive dwarfism and impairment of the synchondroses of the cranial base, resulting in defective formation of the foramen magnum."
    explanation: >
      Mouse model demonstrates that FGFR3 gain-of-function directly disrupts cranial
      base synchondrosis development and foramen magnum formation, explaining the
      craniofacial features of HCH.
phenotypes:
- name: Short stature
  category: Clinical
  description: >
    Disproportionate short stature is the defining growth phenotype of
    hypochondroplasia. In many children it becomes more obvious in toddlerhood or
    early school age as growth velocity falls relative to peers.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hypochondroplasia is a skeletal dysplasia characterized by short stature; stocky build; disproportionately short arms and legs; broad, short hands and feet; mild joint laxity; and relative macrocephaly."
    explanation: >
      GeneReviews identifies short stature as part of the core clinical phenotype of
      hypochondroplasia.
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients presented with a short stature and/or short limbs."
    explanation: >
      In this Korean FGFR3 N540K cohort, short stature and/or short limbs were the
      presenting growth abnormality.
  - reference: PMID:41762373
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hypochondroplasia (HCH) is a disproportionate short-statured skeletal dysplasia condition caused by gain-of-function pathogenic variants in the fibroblast growth receptor 3 gene (FGFR3)."
    explanation: >
      Expert consensus likewise frames HCH as a disproportionate short-stature disorder.
- name: Rhizomelic limb shortening
  category: Clinical
  description: >
    Mild proximal limb shortening and body disproportion may emerge after infancy
    and can be subtle in the neonatal period.
  phenotype_term:
    preferred_term: Rhizomelic limb shortening
    term:
      id: HP:0008905
      label: Rhizomelia
  evidence:
  - reference: PMID:14755409
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypochondroplasia is an autosomal dominant skeletal dysplasia expressing postnatal onset of short stature with mild rhizomelic shortening of the limbs."
    explanation: >
      A molecularly confirmed neonatal case report documents mild rhizomelic limb
      shortening as an early manifestation.
  - reference: PMID:41762373
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Between ages 2-3 years, a characteristic growth pattern including limb shortening and body disproportion may become evident."
    explanation: >
      Expert consensus states that limb shortening and body disproportion typically
      become clinically apparent between ages 2 and 3 years.
- name: Relative macrocephaly
  category: Clinical
  description: >
    Head circumference is often relatively large for height, with measurable
    head-height disproportion even when absolute macrocephaly is not striking.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Relative macrocephaly
    term:
      id: HP:0004482
      label: Relative macrocephaly
  evidence:
  - reference: PMID:41040055
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean (SD) HCH-I was -3.0 (1.2) in the HCH cohort, compared to -0.2 (0.9) in the CIGS cohort. An HCH-I below -2 correctly identified 78% of children with HCH, while only 2.4% of CIGS children fell below the cut-off."
    explanation: >
      This large 2026 cohort study shows marked head-height disproportion in HCH,
      directly supporting relative macrocephaly as a characteristic phenotype.
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively."
    explanation: >
      Macrocephaly was observed in 9/20 patients (45%), which falls in the FREQUENT
      band.
  - reference: PMID:41762373
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "features suggestive of HCH include a sustained fall in length/height centiles over the first 2 years of life, relative macrocephaly, neonatal seizures, and specific radiographic and neuroimaging findings."
    explanation: >
      Expert consensus identifies relative macrocephaly as a key feature suggestive of
      HCH.
- name: Mild joint laxity
  category: Clinical
  description: Mild ligamentous laxity can accompany the skeletal phenotype.
  phenotype_term:
    preferred_term: Mild joint laxity
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hypochondroplasia is a skeletal dysplasia characterized by short stature; stocky build; disproportionately short arms and legs; broad, short hands and feet; mild joint laxity; and relative macrocephaly."
    explanation: >
      GeneReviews lists mild joint laxity among the characteristic clinical features
      of hypochondroplasia.
- name: Genu varum
  category: Clinical
  description: >
    Bowing of the legs is one of the most frequently observed skeletal features,
    reported in over half of patients with confirmed N540K mutations.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Genu varum
    term:
      id: HP:0002970
      label: Genu varum
  evidence:
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively."
    explanation: >
      Genu varum was observed in 11/20 patients (55%), which falls in the FREQUENT
      band.
- name: Neurodevelopmental delay
  category: Neurological
  description: >
    Developmental and learning difficulties are increasingly recognized in
    hypochondroplasia, including in cohorts not selected for neurological disease.
  frequency: HP_0040283
  phenotype_term:
    preferred_term: Neurodevelopmental delay
    term:
      id: HP:0012758
      label: Neurodevelopmental delay
  evidence:
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genu varum, macrocephaly, and developmental delay were observed in 11 (55.0%), 9 (45.0%), and 5 (25.0%) patients, respectively."
    explanation: >
      Developmental delay was observed in 5/20 patients (25%), which falls in the
      OCCASIONAL band.
  - reference: PMID:23165795
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eight patients had neurocognitive difficulties, ranging from specific learning disorder (2/13) to mild intellectual disability (5/13) or global developmental delay (1/13)."
    explanation: >
      A neurologically evaluated Finnish FGFR3 N540K cohort showed a broader spectrum
      of neurocognitive difficulties, reinforcing neurodevelopmental involvement.
  - reference: PMID:41762373
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neurocognitive involvement including neurodevelopmental challenges may become apparent."
    explanation: >
      Expert consensus recognizes neurodevelopmental challenges as part of the HCH
      phenotype.
- name: Seizures
  category: Neurological
  description: >
    Seizures and epilepsy are reported in a subset of individuals with
    hypochondroplasia, including infantile temporal lobe seizures. Whole-disease
    frequency remains uncertain because the strongest MRI data come from a
    neurologically selected cohort.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:23165795
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Six of 13 patients had a history of seizures or epilepsy."
    explanation: >
      Seizures/epilepsy were documented in a neurologically selected Finnish FGFR3
      N540K cohort, supporting a real but frequency-uncertain association.
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Infants may present with temporal lobe seizures."
    explanation: >
      GeneReviews notes that seizures can be an early presenting manifestation.
- name: Temporal lobe dysplasia
  category: Neurological
  description: >
    Brain MRI can show temporal lobe dysgenesis/dysplasia in some FGFR3
    N540K-positive patients. Reported frequency is strongly affected by
    neurologic ascertainment.
  phenotype_term:
    preferred_term: Temporal lobe dysplasia
    term:
      id: HP:0034222
      label: Temporal lobe dysplasia
  evidence:
  - reference: PMID:23165795
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eight patients had undergone MRI. They all had structural abnormalities consistent with temporal lobe dysgenesis."
    explanation: >
      All eight imaged patients in this neurologically selected FGFR3 N540K cohort had
      temporal lobe dysgenesis on MRI, establishing the association but not an
      unbiased population frequency.
- name: Ventriculomegaly
  category: Neurological
  description: >
    Abnormally shaped lateral ventricles have been observed in HCH patients on
    neuroimaging.
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
  evidence:
  - reference: PMID:23165795
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Six patients had peritrigonal white matter reduction, and 4 had abnormally shaped lateral ventricles."
    explanation: >
      Abnormally shaped lateral ventricles were observed on MRI in four neurologically
      evaluated patients with FGFR3 N540K-related HCH.
- name: Hydrocephalus
  category: Neurological
  description: >
    Obstructive hydrocephalus requiring neurosurgical treatment has been reported
    in a small subset of affected children.
  phenotype_term:
    preferred_term: Hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  evidence:
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 12 patients who underwent neuroimaging, five (41.7%) showed abnormal findings (one required operation for obstructive hydrocephalus)."
    explanation: >
      One child in this 20-patient Korean cohort required surgery for obstructive
      hydrocephalus, showing that hydrocephalus can occur as a clinically important
      complication.
- name: Spinal canal stenosis
  category: Clinical
  description: >
    Spinal canal stenosis occurs less often than in achondroplasia but remains a
    clinically important complication in hypochondroplasia.
  phenotype_term:
    preferred_term: Spinal canal stenosis
    term:
      id: HP:0003416
      label: Spinal canal stenosis
  evidence:
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Medical complications common to achondroplasia (e.g., foramen magnum stenosis, spinal stenosis, tibial bowing, obstructive apnea) occur less frequently in hypochondroplasia, but intellectual disability and epilepsy may be more prevalent."
    explanation: >
      GeneReviews explicitly lists spinal stenosis among recognized but less frequent
      hypochondroplasia complications.
- name: Narrow vertebral interpedicular distance
  category: Radiological
  description: >
    Lack of the normal caudal widening or frank narrowing of the lumbar/lumbosacral
    interpedicular distance is a classic radiographic clue to hypochondroplasia.
  phenotype_term:
    preferred_term: Narrow vertebral interpedicular distance
    term:
      id: HP:0008450
      label: Narrow vertebral interpedicular distance
  evidence:
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."
    explanation: >
      GeneReviews identifies lack of widening or narrowing of the lumbar
      interpedicular distances as a characteristic radiographic feature.
  - reference: PMID:11475794
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hypochondroplasia is a genetic skeletal dysplasia characterized by disproportionate short stature, stocky appearance and several clinical and radiological features very similar, but much milder, than those of classical achondroplasia, including shortened and stubby long bones, decreased lumbo-sacral interpediculate distances, posterior scalloping of the lumbar vertebrae, metaphyseal flaring, and moderate macrocephaly."
    explanation: >
      This radiology-focused review independently confirms decreased lumbosacral
      interpediculate distance as a salient hypochondroplasia sign.
- name: Posterior scalloping of vertebral bodies
  category: Radiological
  description: >
    Posterior vertebral body scalloping is a recurrent spinal radiographic finding
    in hypochondroplasia.
  phenotype_term:
    preferred_term: Posterior scalloping of vertebral bodies
    term:
      id: HP:0005121
      label: Posterior scalloping of vertebral bodies
  evidence:
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."
    explanation: >
      GeneReviews lists posterior scalloping of the vertebral bodies among the core
      radiographic features.
  - reference: PMID:11475794
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hypochondroplasia is a genetic skeletal dysplasia characterized by disproportionate short stature, stocky appearance and several clinical and radiological features very similar, but much milder, than those of classical achondroplasia, including shortened and stubby long bones, decreased lumbo-sacral interpediculate distances, posterior scalloping of the lumbar vertebrae, metaphyseal flaring, and moderate macrocephaly."
    explanation: >
      A radiology review likewise identifies posterior scalloping of the lumbar
      vertebrae as part of the classic pattern.
- name: Metaphyseal widening
  category: Radiological
  description: >
    Mild metaphyseal widening/flaring of long bones is part of the characteristic
    radiographic pattern.
  phenotype_term:
    preferred_term: Metaphyseal flaring
    term:
      id: HP:0003016
      label: Metaphyseal widening
  evidence:
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."
    explanation: >
      GeneReviews describes mild metaphyseal flare as a characteristic long-bone
      radiographic feature.
  - reference: PMID:11475794
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Hypochondroplasia is a genetic skeletal dysplasia characterized by disproportionate short stature, stocky appearance and several clinical and radiological features very similar, but much milder, than those of classical achondroplasia, including shortened and stubby long bones, decreased lumbo-sacral interpediculate distances, posterior scalloping of the lumbar vertebrae, metaphyseal flaring, and moderate macrocephaly."
    explanation: >
      An independent radiology review also highlights metaphyseal flaring in
      hypochondroplasia.
- name: Short iliac bones
  category: Radiological
  description: >
    Shortened, often squared ilia are diagnostically useful pelvic radiographic
    findings.
  phenotype_term:
    preferred_term: Short iliac bones
    term:
      id: HP:0100866
      label: Short iliac bones
  evidence:
  - reference: PMID:20301650
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Radiologic features include shortening of long bones with mild metaphyseal flare; a lack of widening or a narrowing of the lumbar interpedicular distances with shortening of the pedicle length and posterior scalloping of the vertebral bodies; short, broad femoral neck; and squared, shortened ilia."
    explanation: >
      GeneReviews identifies squared, shortened ilia as part of the classic HCH
      pelvic phenotype.
  - reference: PMID:26867606
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We evaluated parameters reflecting the presence of (1) short ilia, (2) squared ilia, (3) short greater sciatic notch, (4) horizontal acetabula, (5) short femora, (6) broad femora, (7) metaphyseal flaring, (8) lumbosacral interpedicular distance narrowing and (9) ovoid radiolucency of the proximal femora. RESULTS: Only parameters 1, 3, 4, 5 and 6 were statistically different between the two groups."
    explanation: >
      This abstract explicitly defines parameter 1 as short ilia and reports it among
      the radiographic features that significantly distinguished HCH neonates from
      controls.
- name: Short femur
  category: Radiological
  description: >
    Short femora are part of the early radiographic pattern and contributed to the
    proposed neonatal diagnostic criteria.
  phenotype_term:
    preferred_term: Short femur
    term:
      id: HP:0003097
      label: Short femur
  evidence:
  - reference: PMID:26867606
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We evaluated parameters reflecting the presence of (1) short ilia, (2) squared ilia, (3) short greater sciatic notch, (4) horizontal acetabula, (5) short femora, (6) broad femora, (7) metaphyseal flaring, (8) lumbosacral interpedicular distance narrowing and (9) ovoid radiolucency of the proximal femora. RESULTS: Only parameters 1, 3, 4, 5 and 6 were statistically different between the two groups."
    explanation: >
      This abstract explicitly defines parameter 5 as short femora and reports it
      among the radiographic features that significantly distinguished HCH neonates
      from controls.
  - reference: PMID:14755409
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mild shortening of the limbs became manifest after 26 weeks of gestation."
    explanation: >
      This molecularly confirmed prenatal case supports femoral/limb shortening as an
      early developmental manifestation.
genetic:
- name: FGFR3 N540K mutation
  association: Causative
  notes: >
    The c.1620C>A or c.1620C>G (p.Asn540Lys) mutation in the tyrosine kinase domain
    of FGFR3 is the most common causative variant, found in 50-70% of clinically
    diagnosed hypochondroplasia cases. This recurrent mutation was identified in 8 of
    14 unrelated patients in the landmark 1995 study. Other FGFR3 mutations account
    for additional cases, but a significant proportion of clinically diagnosed patients
    have no identifiable FGFR3 mutation, suggesting genetic heterogeneity or phenotypic
    overlap with other conditions.
  variants:
  - name: c.1620C>A (p.Asn540Lys)
    description: The most common causative mutation.
  - name: c.1620C>G (p.Asn540Lys)
    description: Alternative nucleotide change resulting in the same amino acid substitution.
  evidence:
  - reference: PMID:7670477
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We now report a single FGFR3 mutation found in 8 out of 14 unrelated patients with hypochondroplasia. This mutation causes a C to A transversion at nucleotide 1620, resulting in an Asn540Lys substitution in the proximal tyrosine kinase domain."
    explanation: >
      Landmark Nature Genetics paper identifying the recurrent FGFR3 N540K mutation as
      the cause of hypochondroplasia in the majority of genetically confirmed cases.
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The N540K variant accounts for 60-70% of reported cases and is associated with severe manifestations."
    explanation: >
      Korean clinical series confirms the high frequency of the N540K variant among
      genetically confirmed HCH cases.
  - reference: PMID:41184854
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, 85.5% of ACH cases and 57.2% of HCH cases were related to de novo genetic variants"
    explanation: >
      French nationwide data confirms that the majority of HCH cases arise from de novo
      FGFR3 variants.
- name: FGFR3
  gene_term:
    preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_518a0eb2-f7ea-40e8-acad-afc34f5b188e-2023-09-28T040000.000Z
    reference_title: "FGFR3 / hypochondroplasia (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FGFR3 | HGNC:3690 | hypochondroplasia | MONDO:0007793 | AD | Definitive"
    explanation: ClinGen classifies the FGFR3-hypochondroplasia gene-disease relationship as definitive with autosomal dominant inheritance.
animal_models:
- species: Mouse
  genotype: Fgfr3Asn534Lys/+ (knock-in)
  category: knock-in model
  description: >
    The first mouse model of hypochondroplasia, carrying the murine equivalent
    (Asn534Lys) of the human FGFR3 N540K mutation. This model recapitulates progressive
    dwarfism, impaired cranial base synchondroses with defective foramen magnum
    formation, and altered bone mineralization with decreased trabecular BMD and
    increased cortical BMD.
  genes:
  - preferred_term: FGFR3
    term:
      id: hgnc:3690
      label: FGFR3
  associated_phenotypes:
  - Progressive dwarfism
  - Impaired cranial base synchondroses
  - Defective foramen magnum formation
  - Decreased trabecular bone mineral density
  - Increased cortical bone mineral density
  evidence:
  - reference: PMID:37345656
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Fgfr3Asn534Lys/+ mice exhibited progressive dwarfism and impairment of the synchondroses of the cranial base, resulting in defective formation of the foramen magnum. The appendicular and axial skeletons were both severely affected and we demonstrated an important role of FGFR3 in regulation of cortical and trabecular bone structure."
    explanation: >
      This study generated and characterized the first HCH mouse model, demonstrating
      that the N540K-equivalent mutation is sufficient to cause progressive skeletal
      abnormalities affecting both appendicular and axial skeleton.
treatments:
- name: Vosoritide (CNP analog)
  description: >
    Vosoritide is a C-type natriuretic peptide (CNP) analog that counteracts FGFR3
    overactivation by stimulating the NPR2/cGMP pathway, which antagonizes MAPK/ERK
    signaling in growth plate chondrocytes. A phase 2 trial demonstrated a 1.81 cm/year
    increase in annualized growth velocity with acceptable safety.
  treatment_term:
    preferred_term: CNP analog therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vosoritide
      term:
        id: NCIT:C152918
        label: Vosoritide
  evidence:
  - reference: PMID:38813446
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vosoritide was well tolerated with no treatment-related serious adverse events. Injection site reactions occurred in 83.3% of participants. No participants discontinued therapy due to an adverse event. Annualized growth velocity increased by 2.26 standard deviations (SD) and height SDS increased by 0.36 SD during the treatment period versus the observation period."
    explanation: >
      Phase 2 trial in 24 children with HCH demonstrated that vosoritide significantly
      increased growth velocity with a favorable safety profile.
- name: Growth hormone therapy
  description: >
    Recombinant human growth hormone has been used with variable response. In one
    Korean cohort, 16 patients treated for a mean of 5.4 years showed a significant
    increase in height standard deviation scores.
  treatment_term:
    preferred_term: Growth hormone therapy
    term:
      id: MAXO:0000780
      label: human growth hormone replacement therapy
  evidence:
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among 16 growth-hormone-treated patients (two were growth-hormone deficient), the increase in height standard deviation scores was significant after a mean 5.4±0.7 years of treatment (+0.6 and+1.8 using growth references for healthy controls and achondroplasia children, respectively)."
    explanation: >
      Korean cohort data shows statistically significant height gains with GH therapy in
      HCH, though the magnitude of improvement is modest.
- name: Orthopedic management
  description: >
    Surgical correction of leg bowing or other skeletal deformities may be considered
    if functionally significant. Surgical limb lengthening has been performed in some
    patients.
  treatment_term:
    preferred_term: Orthopedic surgery
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:36442838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four patients underwent surgical limb lengthening at a mean age of 8.8±3.3 years."
    explanation: >
      Surgical limb lengthening was performed in 4 of 20 Korean HCH patients, typically
      in mid-childhood.
clinical_trials:
- name: NCT04219007
  phase: PHASE_II
  status: COMPLETED
  description: >
    Single-arm, open-label phase 2 trial evaluating the safety and efficacy of
    vosoritide (15 μg/kg/day subcutaneous injection) in children with
    hypochondroplasia, following a 6-month observation period and 12 months of
    treatment.
  target_phenotypes:
  - preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:38813446
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We conducted a single-arm, phase 2, open-label trial at a single centre in the USA and enrolled 26 children with hypochondroplasia."
    explanation: >
      This trial established efficacy of vosoritide for growth velocity improvement in
      HCH children, similar to results in achondroplasia.
notes: >
  Hypochondroplasia represents the mild end of the FGFR3-related skeletal dysplasia
  spectrum. The phenotype can be subtle, and many cases may go undiagnosed. Neurological
  involvement including temporal lobe dysgenesis, seizures, and neurocognitive
  difficulties is increasingly recognized, particularly in patients with the N540K
  mutation. The 2023 mouse model revealed previously underappreciated bone mineralization
  defects that may have implications for osteoporosis risk in aging patients. Vosoritide,
  approved for achondroplasia, showed promising results in a phase 2 trial for HCH.
datasets:
references:
- reference: PMID:20301650
  title: "Hypochondroplasia."
  tags:
  - GeneReviews
  findings: []
- reference: DOI:10.1007/s00109-017-1602-9
  title: Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia
  findings: []
- reference: DOI:10.1172/jci.insight.168796
  title: Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice
  findings: []

📚

References & Deep Research

References

3

PMID:20301650

Hypochondroplasia.

No top-level findings curated for this source.

DOI:10.1007/s00109-017-1602-9

Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia

No top-level findings curated for this source.

DOI:10.1172/jci.insight.168796

Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice

No top-level findings curated for this source.

Deep Research

2

Disorder ▸

Disorder

Name: Hypochondroplasia
Category: Mendelian
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 2

Key Pathophysiology Nodes

FGFR3 gain-of-function signaling (mild)
Deep research literature mapping

Citation Inventory (for evidence mapping)

DOI:10.1007/s00109-017-1602-9
DOI:10.1172/jci.insight.168796

Falcon ▸

Disease Pathophysiology Research Report

Edison Scientific Literature 14 citations 2026-01-30T19:30:43.998522

Disease Pathophysiology Research Report

Target Disease - Disease Name: Hypochondroplasia (HCH) - MONDO ID: [not confirmed] - Category: Mendelian (autosomal dominant)

1) Core Pathophysiology: current understanding - Primary mechanism: Hypochondroplasia is driven by activating (gain-of-function) missense variants in FGFR3, most commonly p.Asn540Lys, which “constitutively” activate the receptor tyrosine kinase and disengage its autoinhibitory brake, making FGFR3 a stronger negative regulator of bone growth (JCI Insight, Jun 2023; DOI: 10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). In vivo, FGFR3 activation perturbs the growth plate and broader skeleton leading to short-limbed dwarfism, cranial base involvement, and altered bone mineralization (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5). - Dysregulated signaling pathways: Downstream of mutant FGFR3, Ras–MAPK/ERK signaling is over-activated in growth-plate chondrocytes, with contributions from STAT signaling; the imbalance inhibits chondrocyte proliferation and differentiation and impairs endochondral ossification (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6). - Affected cellular processes: In the growth plate, there is reduced chondrocyte proliferation, altered hypertrophic differentiation, and delayed cartilage-to-bone transition; in bone, osteoblast and osteocyte function and mineralization are disrupted, producing decreased trabecular BMD and age-related increases in cortical BMD with reduced toughness (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5).

Direct supporting quotes - “Hypochondroplasia (HCH) is a mild dwarfism caused by missense mutations in fibroblast growth factor receptor 3 (FGFR3), with the majority of cases resulting from a heterozygous p.Asn540Lys gain-of-function mutation.” (JCI Insight, 2023-06; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2) - “Fgfr3Asn534Lys/+ mice exhibited progressive dwarfism and impairment of the synchondroses of the cranial base, resulting in defective formation of the foramen magnum… Trabecular bone mineral density… was decreased, but cortical BMD increased with age…” (JCI Insight, 2023-06; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3)

2) Key molecular players - Genes/Proteins (HGNC): FGFR3 (HGNC:3689; activating variants drive HCH); MAPK cascade (ERK1/2: MAPK3/MAPK1); STAT family (notably STAT1 downstream of FGFR3) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6). - Chemical entities and modulators: CNP (NPPC) and NPR2/GC-B signaling antagonize FGFR3–MAPK, providing a mechanistic rationale for CNP analog therapy (vosoritide) developed in related FGFR3 dysplasia; selective/pan-FGFR tyrosine kinase inhibitors (e.g., infigratinib/BGJ398) have shown preclinical benefits in FGFR3-driven models; meclozine has been reported to dampen ERK1/2 signaling in preclinical contexts (chen2017moleculartherapeuticstrategies pages 8-9, chen2017moleculartherapeuticstrategies pages 4-6). - Cell types (CL): Growth-plate chondrocytes (CL:0000138) are primary targets; osteoblasts (CL:0000062) and osteocytes (CL:0000137) show altered gene expression/mineralization phenotypes in models (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5). - Anatomical locations (UBERON): Growth plate (UBERON:0003860), cranial base synchondroses (e.g., spheno-occipital synchondrosis, UBERON:0010315), foramen magnum (UBERON:0001680), vertebral body (UBERON:0002371), long bone cortex (UBERON:0002476), trabecular bone (UBERON:0002481) (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3).

3) Biological processes (for GO annotation) - Dysregulated processes include: fibroblast growth factor receptor signaling; MAPK cascade; negative regulation of chondrocyte proliferation; regulation of chondrocyte differentiation and hypertrophy; endochondral ossification; bone mineralization; osteoblast differentiation and osteocyte-mediated bone maintenance (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5, chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6).

4) Cellular components - Key cellular locations: plasma membrane (FGFR3 receptor); cytoplasm (MAPK/ERK signaling); nucleus (STAT-mediated transcriptional effects); extracellular matrix of cartilage and bone (endochondral ossification and mineralization) (chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3).

5) Disease progression: molecular-to-clinical sequence - Trigger: Heterozygous FGFR3 gain-of-function mutations (e.g., p.Asn540Lys) cause constitutive receptor autophosphorylation and hyperactive signaling (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2). - Early growth-plate effects: Excess FGFR3 signaling via MAPK/ERK and STAT reduces chondrocyte proliferation and alters differentiation/hypertrophy, impairing endochondral ossification and longitudinal bone growth (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 1-2). - Cranial base and spine: Premature fusion/impairment of cranial base synchondroses reduces skull base length and foramen magnum area; vertebral bodies shorten and interpedicular distance narrows (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5). - Bone tissue remodeling/mineralization: Decreased trabecular bone volume/BMD and age-related increased cortical BMD with reduced toughness arise from altered osteoblast/osteocyte biology and matrix mineralization; biomechanics are compromised (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5). - Clinical consequence: Disproportionate short stature (“mild dwarfism”), foramen magnum stenosis risk, vertebral/spinal features, and potential fragility due to microarchitectural changes (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5).

6) Phenotypic manifestations and mechanistic links - Short stature with limb disproportion (milder than achondroplasia) stems from suppressed chondrocyte proliferation and impaired endochondral ossification (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 1-2). - Cranial base/foramen magnum involvement results from synchondrosis dysfunction; mechanical stenosis risk follows skull base shortening (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5). - Axial skeleton: reduced vertebral body length and interpedicular distance; trabecular bone deficits and mechanical weakness link to altered osteoblast/osteocyte function and bone matrix properties (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3).

7) Current applications and real-world implementations (2023–2024 prioritized) - Preclinical-to-clinical therapeutic rationale: Antagonizing FGFR3–MAPK signaling via CNP/NPR2 pathway (e.g., CNP analogs such as vosoritide) is mechanistically justified; tyrosine kinase inhibition (e.g., BGJ398/infigratinib) improved outcomes in FGFR3-driven models, though pediatric safety requires caution (J Mol Med, Oct 2017; DOI: 10.1007/s00109-017-1602-9; JCI Insight, Jun 2023; DOI: 10.1172/jci.insight.168796) (chen2017moleculartherapeuticstrategies pages 8-9, chen2017moleculartherapeuticstrategies pages 4-6, loisay2023hypochondroplasiagainoffunctionmutation pages 20-21). - Clinical monitoring implications from 2023 model data: The 2023 HCH mouse study highlights decreased trabecular BMD and paradoxical cortical changes with reduced toughness, suggesting the need to monitor BMD/microarchitecture and potential fracture risk as HCH patients age (JCI Insight, Jun 2023; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5). - Diagnostic genomics: FGFR3 testing is central to confirming HCH; mechanistic insights emphasize identifying activating variants for precise counseling and potential trial eligibility (supported mechanistically by FGFR3 GOF biology) (chen2017moleculartherapeuticstrategies pages 1-2).

8) Expert opinions and analysis - Authoritative consensus places FGFR3 as a negative regulator of growth-plate chondrogenesis; activating variants in the receptor lead to a spectrum from HCH to achondroplasia and lethal dysplasias depending on allele strength and pathway output. Reviews emphasize the antagonism between FGFR3–MAPK and CNP–NPR2–cGMP signaling as a tractable therapeutic axis, with practical considerations around systemic kinase inhibition in children (J Mol Med 2017; DOI: 10.1007/s00109-017-1602-9) (chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6). The 2023 HCH mouse model underscores the breadth of skeletal involvement, including cranial base and bone quality, refining clinical surveillance priorities (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5).

9) Relevant statistics and data (recent) - In the HCH mouse model, lumbar vertebrae exhibited an “18% reduction in bone volume per tissue volume (BV/TV),” “15% decrease in trabecular thickness,” “7% reduction in BMD,” and mechanical deficits including “22% reduction in maximal load” and “34% decrease in stiffness,” linking FGFR3 activation to biomechanical vulnerability (JCI Insight, Jun 2023; https://doi.org/10.1172/jci.insight.168796) (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5). - The same model documented decreased trabecular BMD across long bones and vertebrae with age-related increase in cortical BMD and reduced toughness, suggesting a complex remodeling phenotype relevant to long-term outcomes (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3).

Ontology-style annotations - Gene/Protein annotations (HGNC): FGFR3 (HGNC:3689); MAPK1 (HGNC:6871), MAPK3 (HGNC:6877); STAT1 (HGNC:11362) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 1-2). - Biological processes (GO terms, names): fibroblast growth factor receptor signaling; MAPK cascade; regulation of chondrocyte proliferation; chondrocyte differentiation; endochondral ossification; bone mineralization (chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3). - Cellular components (GO names): plasma membrane; cytoplasm; nucleus; extracellular matrix (chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6). - Cell types (CL): growth-plate chondrocyte (CL:0000138); osteoblast (CL:0000062); osteocyte (CL:0000137) (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3). - Anatomical locations (UBERON): growth plate (UBERON:0003860); cranial base synchondrosis (UBERON:0010315); foramen magnum (UBERON:0001680); vertebral body (UBERON:0002371); long bone cortex (UBERON:0002476); trabecular bone (UBERON:0002481) (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3). - Chemical entities (examples): CNP analog (vosoritide); pan-FGFR inhibitors (infigratinib/BGJ398); meclozine (chen2017moleculartherapeuticstrategies pages 8-9, chen2017moleculartherapeuticstrategies pages 4-6, loisay2023hypochondroplasiagainoffunctionmutation pages 20-21).

Embedded mapping table | Category | Item | Identifier | Notes/Role | Primary Evidence (PMID/DOI) | |---|---|---|---|---| | Genes/Proteins | FGFR3 | HGNC:3689 | Causative gain-of-function mutations in HCH; constitutive RTK activation alters growth-plate signaling | https://doi.org/10.1172/jci.insight.168796; https://doi.org/10.1007/s00109-017-1602-9 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 8-9) | | Genes/Proteins | MAPK pathway (ERK1/2; MAPK1/MAPK3) | MAPK1 (HGNC:6871), MAPK3 (HGNC:6877) | Principal downstream cascade (FGF→Ras→MAPK/ERK) mediating inhibition of chondrocyte proliferation/differentiation | https://doi.org/10.1172/jci.insight.168796; https://doi.org/10.1007/s00109-017-1602-9 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 8-9) | | Genes/Proteins | STAT1 | HGNC:11362 | STAT family activation reported downstream of activated FGFR3, influences chondrocyte proliferation signals | https://doi.org/10.1172/jci.insight.168796; https://doi.org/10.1007/s00109-017-1602-9 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, chen2017moleculartherapeuticstrategies pages 8-9) | | Receptors/Modulators | NPR2 / GC-B | HGNC:7950 | Receptor for CNP; CNP–NPR2 signaling antagonizes FGFR3-MAPK to promote endochondral growth | https://doi.org/10.1007/s00109-017-1602-9 (chen2017moleculartherapeuticstrategies pages 8-9) | | Receptors/Modulators | CNP (NPPC) | NPPC (HGNC:7961) | Endogenous peptide that counteracts FGFR3 effects; therapeutic CNP analogs developed (e.g., vosoritide) | https://doi.org/10.1007/s00109-017-1602-9 (chen2017moleculartherapeuticstrategies pages 8-9) | | Small-molecule / biologic modulators | Vosoritide (CNP analog) | (no CHEBI id shown) | CNP analog in clinical development/approval for FGFR3-related short stature (ACH); mechanistic rationale to oppose MAPK signaling | https://doi.org/10.1007/s00109-017-1602-9 (chen2017moleculartherapeuticstrategies pages 8-9) | | Small-molecule / biologic modulators | Pan-FGFR inhibitors (e.g., NVP-BGJ398 / infigratinib) | — | TKIs that inhibit FGFR3 kinase activity; preclinical/repurposing evidence improves FGFR3-driven growth deficits | https://doi.org/10.1007/s00109-017-1602-9; https://doi.org/10.1172/jci.insight.168796 (chen2017moleculartherapeuticstrategies pages 8-9, loisay2023hypochondroplasiagainoffunctionmutation pages 20-21) | | Small-molecule / biologic modulators | Meclozine | — | Oral drug repurposing candidate reported to inhibit ERK1/2 phosphorylation and rescue growth-plate phenotypes in models | https://doi.org/10.1007/s00109-017-1602-9 (chen2017moleculartherapeuticstrategies pages 8-9) | | Cell types | Growth plate chondrocyte | CL:0000138 | Primary cellular target where FGFR3 GOF reduces proliferation/differentiation and impairs endochondral ossification | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2) | | Cell types | Osteoblast | CL:0000062 | Affected secondarily by dysregulated cartilage-to-bone transition; altered osteoblast gene expression and mineralization observed | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5) | | Cell types | Osteocyte | CL:0000137 | Osteocyte lacunar anomalies reported in FGFR3 GOF mouse model, implicating bone matrix/maintenance defects | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3) | | Cell types | Osteoclast | CL:0000092 | Bone remodeling compartment altered downstream of FGFR3-driven changes in osteoblast/osteocyte signaling | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 20-21) | | Anatomical structures | Growth plate (epiphyseal plate) | UBERON:0003860 | Site of endochondral ossification disrupted in HCH leading to shortened long bones | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2) | | Anatomical structures | Cranial base synchondrosis (spheno-occipital) | UBERON:0010315 | Premature fusion / synchondrosis defects reduce skull base length and foramen magnum area | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5) | | Anatomical structures | Foramen magnum | UBERON:0001680 | Clinically relevant site affected by skull base shortening; risk of stenosis in FGFR3 disorders | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5) | | Anatomical structures | Vertebral body | UBERON:0002371 | Vertebral shortening and reduced interpedicular distance reported; biomechanical weakening observed | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5) | | Anatomical structures | Long bone cortex | UBERON:0002476 | Altered cortical BMD (age-related increases) with reduced toughness described in FGFR3 GOF mice | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 2-3) | | Anatomical structures | Trabecular bone | UBERON:0002481 | Decreased trabecular BMD and BV/TV in FGFR3 GOF models; contributes to fracture risk hypothesis | https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 3-5) |

Table: Table mapping genes, pathways, modulators, cell types and anatomical sites relevant to hypochondroplasia with ontology identifiers and primary evidence DOIs; useful for building structured disease annotations and linking mechanistic claims to source documents. (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 20-21, chen2017moleculartherapeuticstrategies pages 8-9, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5)

Evidence items (with publication details) - Loisay L, et al. Hypochondroplasia gain-of-function mutation in FGFR3 causes defective bone mineralization in mice. JCI Insight. 2023-06. DOI: 10.1172/jci.insight.168796; URL: https://doi.org/10.1172/jci.insight.168796 (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5, loisay2023hypochondroplasiagainoffunctionmutation pages 20-21). - Chen J, et al. Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia. Journal of Molecular Medicine. 2017-10. DOI: 10.1007/s00109-017-1602-9; URL: https://doi.org/10.1007/s00109-017-1602-9 (chen2017moleculartherapeuticstrategies pages 8-9, chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6).

Limitations of current evidence set - The mechanistic synthesis above is strongly supported by the 2023 HCH mouse model and an authoritative FGFR3 review. Additional 2023–2024 clinical studies (e.g., on cardiometabolic risk or AI-driven assessments in skeletal dysplasias) were identified in search but did not yield extractable mechanistic evidence in this run; thus, claims are focused on directly supported FGFR3–HCH biology and therapeutic rationale (loisay2023hypochondroplasiagainoffunctionmutation pages 1-2, loisay2023hypochondroplasiagainoffunctionmutation pages 2-3, loisay2023hypochondroplasiagainoffunctionmutation pages 3-5, chen2017moleculartherapeuticstrategies pages 8-9, chen2017moleculartherapeuticstrategies pages 1-2, chen2017moleculartherapeuticstrategies pages 4-6).

References

(loisay2023hypochondroplasiagainoffunctionmutation pages 1-2): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 9 citations and is from a domain leading peer-reviewed journal.
(loisay2023hypochondroplasiagainoffunctionmutation pages 2-3): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 9 citations and is from a domain leading peer-reviewed journal.
(loisay2023hypochondroplasiagainoffunctionmutation pages 3-5): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 9 citations and is from a domain leading peer-reviewed journal.
(chen2017moleculartherapeuticstrategies pages 1-2): Jia Chen, Jiaqi Liu, Yangzhong Zhou, Sen Liu, Gang Liu, Yuzhi Zuo, Zhihong Wu, Nan Wu, and Guixing Qiu. Molecular therapeutic strategies for fgfr3 gene-related skeletal dysplasia. Journal of Molecular Medicine, 95:1303-1313, Oct 2017. URL: https://doi.org/10.1007/s00109-017-1602-9, doi:10.1007/s00109-017-1602-9. This article has 9 citations.
(chen2017moleculartherapeuticstrategies pages 4-6): Jia Chen, Jiaqi Liu, Yangzhong Zhou, Sen Liu, Gang Liu, Yuzhi Zuo, Zhihong Wu, Nan Wu, and Guixing Qiu. Molecular therapeutic strategies for fgfr3 gene-related skeletal dysplasia. Journal of Molecular Medicine, 95:1303-1313, Oct 2017. URL: https://doi.org/10.1007/s00109-017-1602-9, doi:10.1007/s00109-017-1602-9. This article has 9 citations.
(chen2017moleculartherapeuticstrategies pages 8-9): Jia Chen, Jiaqi Liu, Yangzhong Zhou, Sen Liu, Gang Liu, Yuzhi Zuo, Zhihong Wu, Nan Wu, and Guixing Qiu. Molecular therapeutic strategies for fgfr3 gene-related skeletal dysplasia. Journal of Molecular Medicine, 95:1303-1313, Oct 2017. URL: https://doi.org/10.1007/s00109-017-1602-9, doi:10.1007/s00109-017-1602-9. This article has 9 citations.
(loisay2023hypochondroplasiagainoffunctionmutation pages 20-21): Léa Loisay, Davide Komla-Ebri, Anne Morice, Yann Heuzé, Camille Viaut, Amélie de La Seiglière, Nabil Kaci, Danny Chan, Audrey Lamouroux, Geneviève Baujat, J.H. Duncan Bassett, Graham R. Williams, and Laurence Legeai-Mallet. Hypochondroplasia gain-of-function mutation in fgfr3 causes defective bone mineralization in mice. JCI Insight, Jun 2023. URL: https://doi.org/10.1172/jci.insight.168796, doi:10.1172/jci.insight.168796. This article has 9 citations and is from a domain leading peer-reviewed journal.

Hypochondroplasia

Ask OpenScientist

OpenScientist Report

Inheritance

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)